IndustryCompany release

KORU Medical Q3 revenue rises 11% to $11.6M as company narrows 2026 guidance

🇺🇸 KORU Medical Systems, Inc. (KRMD) · Tue 10 Nov 2026

The maker of the Freedom subcutaneous infusion system posted a small profit, improved its gross margin and trimmed its full-year revenue range while lowering its margin outlook.

KORU Medical Systems, which makes the Freedom subcutaneous infusion system, reported results for the third quarter ended 30 September 2026 on 10 November. Revenue grew 11.2% to $11.6 million.

Gross margin improved to 65.2%. The company recorded net income of $0.2 million and adjusted EBITDA of $1.3 million. The summary of the release describes this as a second consecutive profitable quarter.

For the full year 2026, KORU narrowed its revenue guidance to $48.0 million to $48.5 million. It also lowered its gross margin range to 63% to 64%, while raising its year-end cash outlook to above $8.0 million.

The full release text was not available for this report, so details on the drivers of growth, product mix or the prior guidance ranges are not covered here.

What it means for your team

  • Market-access teams working with subcutaneous immunoglobulin and other infusion therapies can read the growth as a sign of continued demand for the Freedom delivery platform, though the drivers have not been disclosed.
  • Supply and quality teams may wish to watch for any further detail on the lowered gross margin guidance, as the source summary does not explain the change.
  • The higher year-end cash outlook points to a stronger balance sheet for a device supplier, which is relevant to partner and supplier risk assessments.

Company's press release (SEC filing): KORU Medical Systems, Inc. ↗

Article written by VigiEye from the official source (KORU Medical Systems, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →